Therefore, we tested here the controversial concept that instead of preventing ongoing mutation in tumor cells, actively driving a high mutational load through APOBEC3B expression may enhance therapy by rendering poorly immunogenic tumors susceptible to immunotherapy. This evidence concerns the gene APOBEC3B and neoplasm.